Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry.

Manasi AgrawalErica J BrennerXian ZhangJean-Frederic ColombelMichael D KappelmanRyan C Ungaronull nullRichard B GearryGilaad G KalpanMichele Kissous-HuntJames D LewisSiew C NgJean-Francois RahierWalter ReinischFrank M RuemmeleFlavio SteinwurzFox E Underwood

Published in: Journal of Crohn's & colitis (2021)

IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes.

Keyphrases

ulcerative colitis
coronavirus disease
sars cov
emergency department
type diabetes
adipose tissue
respiratory syndrome coronavirus
insulin resistance
case control